tradingkey.logo

Twist Bioscience Corp

TWST
49.240USD
+2.140+4.54%
終値 02/06, 16:00ET15分遅れの株価
3.02B時価総額
損失額直近12ヶ月PER

Twist Bioscience Corp

49.240
+2.140+4.54%

詳細情報 Twist Bioscience Corp 企業名

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Twist Bioscience Corpの企業情報

企業コードTWST
会社名Twist Bioscience Corp
上場日Oct 31, 2018
最高経営責任者「CEO」Leproust (Emily M)
従業員数979
証券種類Ordinary Share
決算期末Oct 31
本社所在地681 Gateway Blvd.
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号94080
電話番号18007190671
ウェブサイトhttps://www.twistbioscience.com/
企業コードTWST
上場日Oct 31, 2018
最高経営責任者「CEO」Leproust (Emily M)

Twist Bioscience Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
419.69K
-154368.00%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
101.36K
-22390.00%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
94.05K
+1343.00%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
70.48K
-16772.00%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
61.82K
-29002.00%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
31.82K
-5738.00%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
23.68K
+1436.00%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
17.16K
+1344.00%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
10.39K
+4834.00%
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Lead Independent Director
Lead Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
419.69K
-154368.00%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
101.36K
-22390.00%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
94.05K
+1343.00%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
70.48K
-16772.00%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
61.82K
-29002.00%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
31.82K
-5738.00%

収益内訳

通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
NGS tools
208.10M
55.26%
Synthetic genes
113.60M
30.17%
Antibody discovery
23.45M
6.23%
Oligo pools
20.23M
5.37%
DNA libraries
11.18M
2.97%
地域別USD
会社名
収益
比率
Americas
225.58M
59.90%
EMEA
124.24M
32.99%
APAC
26.75M
7.10%
事業別
地域別
事業別USD
会社名
収益
比率
NGS tools
208.10M
55.26%
Synthetic genes
113.60M
30.17%
Antibody discovery
23.45M
6.23%
Oligo pools
20.23M
5.37%
DNA libraries
11.18M
2.97%

株主

更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
ARK Investment Management LLC
12.33%
Artisan Partners Limited Partnership
9.51%
The Vanguard Group, Inc.
9.40%
BlackRock Institutional Trust Company, N.A.
7.85%
William Blair Investment Management, LLC
6.76%
他の
54.16%
株主統計
株主統計
比率
ARK Investment Management LLC
12.33%
Artisan Partners Limited Partnership
9.51%
The Vanguard Group, Inc.
9.40%
BlackRock Institutional Trust Company, N.A.
7.85%
William Blair Investment Management, LLC
6.76%
他の
54.16%
種類
株主統計
比率
Investment Advisor
66.28%
Investment Advisor/Hedge Fund
36.10%
Hedge Fund
9.90%
Research Firm
5.44%
Pension Fund
1.58%
Individual Investor
1.58%
Bank and Trust
0.83%
Family Office
0.17%
Insurance Company
0.07%

機関投資家保有株

更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
583
73.84M
120.43%
-2.98M
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
ARK Investment Management LLC
6.73M
10.98%
+326.37K
+5.10%
Sep 30, 2025
Artisan Partners Limited Partnership
6.41M
10.46%
+1.35M
+26.67%
Sep 30, 2025
The Vanguard Group, Inc.
5.76M
9.39%
-63.16K
-1.09%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.81M
7.85%
-46.27K
-0.95%
Sep 30, 2025
William Blair Investment Management, LLC
4.14M
6.76%
+235.68K
+6.03%
Sep 30, 2025
EdgePoint Investment Group Inc.
4.08M
6.66%
+1.70M
+71.10%
Sep 30, 2025
State Street Investment Management (US)
3.09M
5.04%
+588.07K
+23.51%
Sep 30, 2025
Amova Asset Management Co., Ltd.
2.12M
3.46%
-179.23K
-7.79%
Sep 30, 2025
Soleus Capital Management, L.P.
1.87M
3.05%
+1.51M
+426.59%
Sep 30, 2025
Millennium Management LLC
1.79M
2.93%
+1.08M
+151.55%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
ARK Genomic Revolution ETF
6.24%
iShares Genomics Immunology and Healthcare ETF
3.92%
Global X Genomics & Biotechnology ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2%
WisdomTree BioRevolution Fund
1.79%
ARK Innovation ETF
1.47%
Franklin Genomic Advancements ETF
1.17%
State Street SPDR S&P Biotech ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.66%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
詳細を見る
ARK Genomic Revolution ETF
比率6.24%
iShares Genomics Immunology and Healthcare ETF
比率3.92%
Global X Genomics & Biotechnology ETF
比率2.09%
ROBO Global Healthcare Technology & Innovation ETF
比率2%
WisdomTree BioRevolution Fund
比率1.79%
ARK Innovation ETF
比率1.47%
Franklin Genomic Advancements ETF
比率1.17%
State Street SPDR S&P Biotech ETF
比率0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
比率0.66%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.56%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI